AstraZeneca proposes $10 billion acquisition of rare-obesity drugmaker Rhythm
AI Summary- AstraZeneca proposed acquiring Rhythm Pharmaceuticals for $10 billion.
- Rhythm's vivmelagon technology-transfer agreement with LG Chem reached approximately 1.15 trillion Korean won.
- Rare-obesity developers face reported deaths, cardiac abnormalities, clinical holds and discontinued programs.